A phase I study of ultra-low dose subcutaneous interleukin-2 (IL-2) for treatment of refractory chronic graft versus host disease
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 08 Nov 2017
At a glance
- Drugs Interleukin-2 (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions
- 03 Oct 2017 Planned End Date changed from 1 Aug 2017 to 1 Aug 2018.
- 10 Jun 2017 Biomarkers information updated
- 01 Aug 2016 Planned End Date changed from 1 Jun 2016 to 1 Aug 2017.